Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05252416 · ClinicalTrials.gov registry record · Phase 1
(VELA) Study of BLU-222 in Advanced Solid Tumors
A Phase 1 study, sponsored by Blueprint Medicines Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT05252416 is a Phase 1 study that was terminated before completion, run by Blueprint Medicines Corporation. The registered enrollment target is 50 participants.
The verdict
NCT05252416, a Phase 1 study, was terminated before completion, sponsored by Blueprint Medicines Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
Interventions
- DRUG Carboplatin
- DRUG Fulvestrant
- DRUG Ribociclib
- DRUG BLU-222
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-04-07 |
| Est. Completion | 2025-07-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05252416
The ClinicalTrials.gov registry entry for NCT05252416 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blueprint Medicines Corporation, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT05252416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05252416 about?
NCT05252416 is a clinical study titled "(VELA) Study of BLU-222 in Advanced Solid Tumors". This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
What is the current status of trial NCT05252416?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2022-04-07. Estimated completion is 2025-07-04.
What interventions are being tested in trial NCT05252416?
The interventions under investigation include: Carboplatin (DRUG), Fulvestrant (DRUG), Ribociclib (DRUG), BLU-222 (DRUG).
Who is sponsoring clinical trial NCT05252416?
This trial is sponsored by Blueprint Medicines Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.